Am J Surg

1. ORAVEC N, Stockley C, Lee J, Taqi K, et al
   Patterns of referral for cytoreductive surgery and HIPEC among patients with metachronous peritoneal carcinomatosis and T4 colon cancer: A population-based study in Alberta, Canada.
   Am J Surg. 2026;259:117037.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. TANWEER MD, Paz IB, Lwin T, Melstrom L, et al
   ASO Visual Abstract: Locoregional Control from Complete Peritoneal Cytoreduction in Patients with Extraperitoneal Colorectal Cancer Metastases: An Entropy Balanced Analysis.
   Ann Surg Oncol. 2026 May 21. doi: 10.1245/s10434-026-19825.
   

   >> Share

   
   
3. KHAN MS, Leonard T, Williams N, Mallick S, et al
   Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and Pancreatic Cancer Survival.
   Ann Surg Oncol. 2026 May 17. doi: 10.1245/s10434-026-19760.
   

   >> Share

   
   
4. ELLIAS S, Crocker AB, Jonnala R, Rivera B, et al
   Robotic Caudate Lobectomy for a Solitary Colorectal Liver Metastasis Using Arantius?Ligament Hanging and ICG Negative Staining.
   Ann Surg Oncol. 2026;33:5826-5828.
   

   >> Share

   
   

   
   BMC Cancer

5. SAOUB S, Metzen E, Thakur BK, Henning Y, et al
   P53 - a new player in the metabolic adaptation of colorectal carcinoma cells under hypoxia.
   BMC Cancer. 2026;26:628.
   

   >> Share

   
   
6. WANG S, Gu R, Lu J, Wang S, et al
   Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials.
   BMC Cancer. 2026;26:663.
   

   >> Share

   
   

   
   BMC Gastroenterol

7. MOMMA T, Okayama H, Hasegawa M, Kawamata T, et al
   Clinicopathological characteristics and stage-adjusted outcomes of sporadic pMMR/MSS early-onset colorectal cancer.
   BMC Gastroenterol. 2026 May 21. doi: 10.1186/s12876-026-04938.
   

   >> Share

   
   
8. ROEPSTORFF S, Bryrup T, Rasmussen M
   A randomized controlled superiority trial of 1 L (Plenvu) versus 2 L (Moviprep) polyethelene glycol plus ascorbate in a FIT-based colorectal cancer screening setting (PLEMO).
   BMC Gastroenterol. 2026 May 20. doi: 10.1186/s12876-026-04948.
   

   >> Share

   
   
9. CHEEMA A, Levy K, Calderwood AH
   Navigating false-positive outcomes after stool-based colorectal cancer screening tests: a scoping review.
   BMC Gastroenterol. 2026 May 16. doi: 10.1186/s12876-026-04900.
   

   >> Share

   
   

   
   Cancer Lett

10. TANG Z, Li T, Yang Z, Zhang Y, et al
    Secreted PEBP4 promotes colorectal cancer progression via regulation of the TGF-beta signaling pathway.
    Cancer Lett. 2026;653:218592.
    

    >> Share

    
    

    
    Clin Cancer Res

11. YAMAGUCHI A, Coll RP, Wang J, Bae SW, et al
    Glycoprotein mucin 13 expression as a theranostic target in colorectal cancer.
    Clin Cancer Res. 2026 May 18. doi: 10.1158/1078-0432.CCR-26-0559.
    

    >> Share

    
    

    
    Eur J Cancer

12. OLESEN TB, Therkildsen SB, Viborg PH, Brander N, et al
    Performance of FIT-based colorectal cancer screening in Denmark from 2014 to 2022.
    Eur J Cancer. 2026;241:116788.
    

    >> Share

    
    
13. MARCHETTI C, Gultekin M, Sassu CM, Planchamp F, et al
    ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.
    Eur J Cancer. 2026;240:116739.
    

    >> Share

    
    

    
    Gastrointest Endosc

14. POORTMANS PJ, Montori M, Debels LK, Argenziano ME, et al
    Repositionable Elastic Adaptive Customizable Traction multipoint elastic traction for colorectal endoscopic submucosal dissection: a retrospective single-center feasibility series of 59 consecutive cases (with video).
    Gastrointest Endosc. 2026;103:1232-1240.
    

    >> Share

    
    

    
    Gut

15. YANG H, Dungan M, Madhu B, Beyries K, et al
    MAIT cell enrichment in Lynch syndrome is associated with immune surveillance and colorectal cancer risk.
    Gut. 2026 May 19:gutjnl-2025-337343. doi: 10.1136/gutjnl-2025-337343.
    

    >> Share

    
    

    
    Int J Colorectal Dis

16. MA J, Zhang Q, Su J, Wang Y, et al
    Risk factors and prediction model for post-polypectomy metachronous colorectal adenoma.
    Int J Colorectal Dis. 2026;41:87.
    

    >> Share

    
    
17. BAZARBASHI S, Alsharm A, Alshehri A, Ibnshamsah F, et al
    Consensus statement on the management of metastatic colorectal cancer beyond the second-line therapy in Saudi Arabia.
    Int J Colorectal Dis. 2026 May 20. doi: 10.1007/s00384-026-05130.
    

    >> Share

    
    
18. GUERRON-GOMEZ G, Mendivelso-Gonzalez DF, Chaves-Cabezas V, Chaves JJ, et al
    Microsatellite instability and mismatch repair deficiency prevalence among Hispanic/Latino individuals with colorectal cancer: a systematic review and meta-analysis.
    Int J Colorectal Dis. 2026 May 21. doi: 10.1007/s00384-026-05146.
    

    >> Share

    
    

    
    Int J Oncol

19. WANG J, Si Y, Xuan M, Han S, et al
    Integrin beta 4 promotes colorectal cancer progression by upregulating Ezrin and activating the Wnt/beta?catenin signaling pathway.
    Int J Oncol. 2026;69:82.
    

    >> Share

    
    

    
    J Clin Oncol

20. GELLI M, Ewald J, Tanguy ML, Passot G, et al
    Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.
    J Clin Oncol. 2026 Apr 22:JCO2501737. doi: 10.1200/JCO-25-01737.
    

    >> Share

    
    
21. SINICROPE FA, Segovia D, Sharma N, Alberts SR, et al
    Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).
    J Clin Oncol. 2026;44:1401-1415.
    

    >> Share

    
    

    
    Oncogene

22. LI R, Ding R, Dan H, Du K, et al
    NDRG2 orchestrates circadian clock stability to suppress tumorigenesis and potentiate oxaliplatin response in colorectal cancer.
    Oncogene. 2026 May 19. doi: 10.1038/s41388-026-03823.
    

    >> Share

    
    

    
    PLoS One

23. YANG J, Wu Q, Zhou Q, Yin L, et al
    Inhibitory effects of mycosubtilin on proliferation of colon cancer SW480 cells.
    PLoS One. 2026;21:e0348056.
    

    >> Share

    
    
24. KIM J, Lee JS, Chee CG, Woo J, et al
    Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis.
    PLoS One. 2026;21:e0348521.
    

    >> Share

    
    
25. FALIHZADEH Z, Roomiani L
    ROS-mediated apoptosis in colon cancer cells induced by sulfated polysaccharides from Gracilaria corticata.
    PLoS One. 2026;21:e0344172.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

26. XIAO Z, Xu H, Ma N, Lei L, et al
    A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade.
    Proc Natl Acad Sci U S A. 2026;123:e2531588123.
    

    >> Share

    
    

    
    World J Surg

27. EMILE SH, Perets M, Kahana N, Boutros M, et al
    A SEER Registry-Based Analysis of the Management Strategies and Survival Outcomes of Colorectal Cancer With Isolated Synchronous Lung Metastases.
    World J Surg. 2026 May 17. doi: 10.1002/wjs.70415.
    

    >> Share

    
    
28. LU L, Zhang L, Chai J, Zhao Q, et al
    HIF-1alpha and PD-L1 as Predictive Efficacy Marker for Neoadjuvant Chemoradiotherapy in Rectal Cancer.
    World J Surg. 2026;50:1169-1178.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share